Infantile spasms
Drug research and approvals for infantile spasms: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 6 studies of infantile spasms are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 3 approved and 11 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 6
- Trials authorized in Canada: 0
- FDA orphan approvals: 3
- EU medicines: 1
- IBIS - Investigating Reliability of BIS and SEDLINE Monitoring in Children With Developmental and Epileptic…NCT07585643 · Not reported · Telethon Kids Institute · starts Sep 16, 2026
- A Study to Prevent Infantile Spasms RelapseNCT06819670 · Phase 2 · University of California, Los Angeles · starts May 5, 2025
- Characterization by Automated System on Infantile SpasmesNCT06266234 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Feb 1, 2024
- Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and AdolescentsNCT05126914 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Dec 11, 2025
- Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile SpasmNCT04302116 · Not applicable · Kullasate Sakpichaisakul · starts May 18, 2020
- Treatment of Refractory Infantile Spasms With FenfluramineNCT04289467 · Phase 2 · Children's Hospital of Orange County · starts Jun 16, 2023
Approved 3
- VigabatrinGamma-amino-N-butyrate transaminase inhibitor
- GanaxoloneGABA-A receptor; anion channel positive allosteric modulator
- CorticotropinMelanocortin receptor 2 agonist
Phase 3 3
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- CosyntropinMelanocortin receptor 2 agonist
- PyridoxineSupplement
Phase 2 2
- FenfluramineSerotonin 1d (5-HT1d) receptor agonist
- RadiprodilGlutamate NMDA receptor; GRIN1/GRIN2B antagonist
Phase 1 or earlier 1
How its trials ended
44 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 16 whose ending is known, 19% met their primary endpoint, 6% missed it and 75% stopped early.
- Completed, result not reported1432%
- Ongoing1023%
- Stopped: other or unclear818%
- Status unknown49%
- Met its primary endpoint37%
- Stopped: enrollment or feasibility25%
- Stopped: sponsor or business decision25%
- Missed its primary endpoint12%
| Jun 17, 2024 | VigafydeAs monotherapy for the treatment of infantile spasms in pediatric patients 1 month to 2 years of age for whom the potential benefits… | Pyros Pharmaceuticals, Inc. | Approved |
| Oct 15, 2010 | H.P. Acthar GelTo treat infantile spasms | Questcor Pharmaceuticals, Inc. | Approved |
| Aug 21, 2009 | SabrilFor infantile spasms (IS) - 1 month to 2 years of age. | H. Lundbeck A/S | Approved |
| Oct 27, 2020 | TricaprilinTreatment of infantile spasms also known as West's syndrome | Cerecin, Inc. | Designated |
| Nov 1, 2017 | Vigabatrin and cosyntropinTreatment of infantile spasms | West Therapeutic Development, LLC | Designated |
| Aug 2, 2017 | CosyntropinTreatment of infantile spasms. | West Therapeutic Development, LLC | Designated |
| Mar 20, 2017 | 1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propaneTreatment of infantile spasms | Bio-Pharm Solutions, Co., Ltd. | Designated |
| Jun 20, 2016 | Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine…Treatment of infantile spasms | Anavex Life Sciences Corp. | Designated |
| Jun 13, 2016 | CannabidiolTreatment of infantile spasms | Jazz Pharmaceuticals Research UK Limited | Designated |
| Jul 23, 2015 | CannabidiolTreatment of infantile spasms | Benuvia Operations LLC | Designated |
| Oct 31, 2012 | Tetracosactide hexaacetate (beta 1-24-corticotrophin)Treatment of infantile spasms | Cerium Pharmaceuticals, Inc. | Designated |
| Mar 16, 2012 | CarisbamateManagement of patients with infantile spasms | SK Life Science, Inc. | Designated |
| Sep 15, 2010 | (1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic…Treatment of infantile spasms | Catalyst Pharmaceuticals, Inc. | Designated |
| May 25, 1994 | GanaxoloneTreatment of infantile spasms. | Immedica Pharma AB | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 20, 2018 | KigabeqVigabatrin | Orphelia Pharma S.A.S. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA